BlackRock reports 1.3% stake in MaxCyte shares
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock. As of June 30, 2026, BlackRock beneficially owned 1,402,591 shares of MaxCyte common stock, representing 1.3% of the outstanding class. BlackRock has sole voting power and sole dispositive power over all 1,402,591 shares, with no shared voting or dispositive power.
The filing notes that various underlying clients have the right to receive dividends or sale proceeds from these shares, but no single person has an interest in more than five percent of MaxCyte’s total outstanding common shares. This amendment reflects BlackRock’s status as a holder of 5 percent or less of the class.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
Power of Attorney regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MaxCyte (MXCT) does BlackRock currently own?
What class of MaxCyte (MXCT) securities is reported in BlackRock’s 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.